CN103665111A - 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 - Google Patents
一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 Download PDFInfo
- Publication number
- CN103665111A CN103665111A CN201210327902.7A CN201210327902A CN103665111A CN 103665111 A CN103665111 A CN 103665111A CN 201210327902 A CN201210327902 A CN 201210327902A CN 103665111 A CN103665111 A CN 103665111A
- Authority
- CN
- China
- Prior art keywords
- antibacterial peptide
- transformed body
- cath
- antimicrobial peptide
- cathelicidins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000271899 Hydrophis cyanocinctus Species 0.000 title claims abstract description 8
- 108060001132 cathelicidin Proteins 0.000 title abstract description 12
- 102000014509 cathelicidin Human genes 0.000 title abstract description 12
- 102000044503 Antimicrobial Peptides Human genes 0.000 title abstract 7
- 108700042778 Antimicrobial Peptides Proteins 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 5
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
- 230000009466 transformation Effects 0.000 claims description 24
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000002949 hemolytic effect Effects 0.000 abstract description 4
- 241001136306 Hydrophiidae Species 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 241000938605 Crocodylia Species 0.000 description 2
- 241000272060 Elapidae Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001698 laser desorption ionisation Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000271915 Hydrophis Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 108010078256 antimicrobial peptide IB-367 Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- -1 der Species 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- GUCYBPFJNGVFEB-XELKFLSISA-N iseganan Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(C)C)C1=CC=C(O)C=C1 GUCYBPFJNGVFEB-XELKFLSISA-N 0.000 description 1
- 229950000488 iseganan Drugs 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 108010075334 omiganan pentahydrochloride Proteins 0.000 description 1
- WTNSIKUBZJCPLJ-IQOWARLESA-N omiganan pentahydrochloride Chemical compound Cl.Cl.Cl.Cl.Cl.C1=CC=C2C(C[C@H](NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(N)=O)=CNC2=C1 WTNSIKUBZJCPLJ-IQOWARLESA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
菌株 | MIC(μg/ml) |
绿脓杆菌ATCC27853 | 9.4 |
绿脓杆菌1019(IS,DR) | 18.7 |
绿脓杆菌1205(IS,DR) | 37.5 |
绿脓杆菌1014(IS,DR) | 9.4 |
大肠杆菌ATCC25922 | 2.3 |
大肠杆菌1852(IS,DR) | 2.3 |
大肠杆菌1866(IS,DR) | 9.4 |
大肠杆菌1017(IS,DR) | 4.7 |
大肠杆菌2813(IS,DR) | 9.4 |
大肠杆菌0726(IS,DR) | 4.7 |
大肠杆菌0722(IS,DR) | 4.7 |
金黄色葡萄球菌ATCC25923 | 1.2 |
金黄色葡萄球菌1865(IS,DR) | 18.7 |
金黄色葡萄球菌1875(IS,DR) | 75 |
金黄色葡萄球菌1002(IS,DR) | 9.4 |
金黄色葡萄球菌1013(IS,DR) | 37.5 |
金黄色葡萄球菌2706(IS,DR) | 18.7 |
金黄色葡萄球菌2712(IS,DR) | 9.4 |
金黄色葡萄球菌2810(IS,DR) | 9.4 |
甲型副伤寒沙门氏菌1764(IS,DR) | 4.7 |
肺炎克雷伯菌1123(IS,DR) | 9.4 |
肺炎克雷伯菌1012(IS,DR) | 18.7 |
肺炎克雷伯菌0202(IS,DR) | 37.5 |
肺炎克雷伯菌0724(IS,DR) | 18.7 |
屎肠球菌0712(IS,DR) | 4.7 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210327902.7A CN103665111B (zh) | 2012-09-07 | 2012-09-07 | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210327902.7A CN103665111B (zh) | 2012-09-07 | 2012-09-07 | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103665111A true CN103665111A (zh) | 2014-03-26 |
CN103665111B CN103665111B (zh) | 2016-02-24 |
Family
ID=50303971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210327902.7A Active CN103665111B (zh) | 2012-09-07 | 2012-09-07 | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103665111B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923189A (zh) * | 2014-04-11 | 2014-07-16 | 东北农业大学 | 一种猪源抗菌肽的衍生肽ir2及其制备方法和应用 |
CN105198979A (zh) * | 2014-05-30 | 2015-12-30 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha1及其制备方法和应用 |
CN105273073A (zh) * | 2014-05-30 | 2016-01-27 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha2及其制备方法和应用 |
CN105273074A (zh) * | 2014-05-30 | 2016-01-27 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha3及其制备方法和应用 |
CN105796603A (zh) * | 2014-12-29 | 2016-07-27 | 山东国际生物科技园发展有限公司 | 一种抗菌肽凝胶剂及其制备方法 |
CN105816853A (zh) * | 2015-01-04 | 2016-08-03 | 山东国际生物科技园发展有限公司 | 一种改造体抗菌肽及其凝胶剂的制备 |
CN106478795A (zh) * | 2015-09-01 | 2017-03-08 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽hc3-5及其制备方法和应用 |
CN112625107A (zh) * | 2020-11-30 | 2021-04-09 | 宜肌坊(厦门)生物科技有限公司 | 一种绿海龟抗菌肽的改造体抗菌肽c-cm8及其制备方法和应用 |
CN112625108A (zh) * | 2020-11-30 | 2021-04-09 | 宜肌坊(厦门)生物科技有限公司 | 一种绿海龟抗菌肽的改造体抗菌肽c-cm5及其制备方法和应用 |
CN106800591B (zh) * | 2015-11-25 | 2021-07-09 | 山东国际生物科技园发展有限公司 | 一种海蛇抗菌肽改造体及其原核表达制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101386640A (zh) * | 2008-09-27 | 2009-03-18 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
CN101412753A (zh) * | 2008-09-27 | 2009-04-22 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF及其基因和应用 |
-
2012
- 2012-09-07 CN CN201210327902.7A patent/CN103665111B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101386640A (zh) * | 2008-09-27 | 2009-03-18 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
CN101412753A (zh) * | 2008-09-27 | 2009-04-22 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF及其基因和应用 |
Non-Patent Citations (2)
Title |
---|
DI NARDO A ET AL.: "Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization", 《THE JOURNAL OF IMMUNOLOGY》 * |
YIPENG WANG ET AL.: "Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics", 《PLOS ONE》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923189B (zh) * | 2014-04-11 | 2016-05-18 | 东北农业大学 | 一种猪源抗菌肽的衍生肽ir2及其制备方法和应用 |
CN103923189A (zh) * | 2014-04-11 | 2014-07-16 | 东北农业大学 | 一种猪源抗菌肽的衍生肽ir2及其制备方法和应用 |
CN105273074B (zh) * | 2014-05-30 | 2018-12-18 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha3及其制备方法和应用 |
CN105273074A (zh) * | 2014-05-30 | 2016-01-27 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha3及其制备方法和应用 |
CN105273073A (zh) * | 2014-05-30 | 2016-01-27 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha2及其制备方法和应用 |
CN105273073B (zh) * | 2014-05-30 | 2018-12-18 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha2及其制备方法和应用 |
CN105198979A (zh) * | 2014-05-30 | 2015-12-30 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽qha1及其制备方法和应用 |
CN105796603A (zh) * | 2014-12-29 | 2016-07-27 | 山东国际生物科技园发展有限公司 | 一种抗菌肽凝胶剂及其制备方法 |
CN105816853A (zh) * | 2015-01-04 | 2016-08-03 | 山东国际生物科技园发展有限公司 | 一种改造体抗菌肽及其凝胶剂的制备 |
CN106478795A (zh) * | 2015-09-01 | 2017-03-08 | 山东国际生物科技园发展有限公司 | 一种海蛇改造体抗菌肽hc3-5及其制备方法和应用 |
CN106800591B (zh) * | 2015-11-25 | 2021-07-09 | 山东国际生物科技园发展有限公司 | 一种海蛇抗菌肽改造体及其原核表达制备方法和用途 |
CN112625107A (zh) * | 2020-11-30 | 2021-04-09 | 宜肌坊(厦门)生物科技有限公司 | 一种绿海龟抗菌肽的改造体抗菌肽c-cm8及其制备方法和应用 |
CN112625108A (zh) * | 2020-11-30 | 2021-04-09 | 宜肌坊(厦门)生物科技有限公司 | 一种绿海龟抗菌肽的改造体抗菌肽c-cm5及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103665111B (zh) | 2016-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103665111B (zh) | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 | |
Okigbo et al. | Antimicrobial effect of leaf extracts of pigeon pea (Cajanus cajan (L.) Millsp.) on some human pathogens | |
CN104151415B (zh) | 一种天然抗菌肽Alligatorin4及其应用 | |
CN106188265B (zh) | 一种抗微生物肽Cm-CATH2及其基因、制备方法和应用 | |
CN101386640A (zh) | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 | |
CN101412753A (zh) | 金环蛇抗菌肽cathelicidin-BF及其基因和应用 | |
CN102924574B (zh) | 抗菌肽lz1和该抗菌肽在制备抗菌药物中的用途 | |
Olugbuyiro et al. | Wound healing effect of Flabellaria paniculata leaf extracts | |
CN103435686B (zh) | 抗耐药性细菌感染多肽Cbf-14及其用途 | |
CN107652359A (zh) | 抗菌肽kr‑32及其用途 | |
CN114853865B (zh) | 一种改造体抗菌肽dsNCM1及其应用 | |
CN104292301A (zh) | 一种小分子合成抗菌肽及其制备方法与应用 | |
CN114181293B (zh) | 一种人源抗菌肽ll-37改造体及其应用 | |
CN104163861B (zh) | 一种爬行动物抗菌肽Alligatorin5及其应用 | |
CN107188944A (zh) | 海蚯蚓抗菌肽nz17074衍生肽n6及其应用 | |
CN104177485A (zh) | 一种扬子鳄抗菌肽Alligatorin6及其应用 | |
CN106188264A (zh) | 一种抗微生物肽Cm‑CATH3及其基因、制备方法和应用 | |
CN103936827B (zh) | 一种韭菜籽抗菌三肽及其制备方法与应用 | |
CN102363040A (zh) | 用于粘膜组织的抗微生物肽制剂 | |
CN104592359A (zh) | 一种林蛙抗菌肽衍生物及其应用 | |
CN104388344B (zh) | 一株北里乳杆菌菌株及其用途 | |
US20100196414A1 (en) | Silver Ionized Plant Extraction Liquid and Use Thereof | |
CN102516382A (zh) | 一种海南湍蛙抗微生物肽Hainanenin-5及其基因、分离纯化、化学合成和应用 | |
CN102816223A (zh) | 细鳞鱼Cathelicidin抗微生物肽CATH_BRALE及其基因、制备、应用 | |
WO2012162471A2 (en) | Pachycereus plant extract and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: YANTAI AOLAN MARINE BIOTECHNOLOGY CO., LTD. Effective date: 20140409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140409 Address after: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant after: Shandong International Biotechnology Park Development Co., Ltd. Applicant after: YANTAI AOLAN MARINE ORGANISM TECHNOLOGY CO., LTD. Address before: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant before: Shandong International Biotechnology Park Development Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: YANTAI AOLAN MARINE BIOTECHNOLOGY CO., LTD. LVYE I Free format text: FORMER OWNER: YANTAI AOLAN MARINE BIOTECHNOLOGY CO., LTD. Effective date: 20140909 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140909 Address after: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant after: Shandong International Biotechnology Park Development Co., Ltd. Applicant after: YANTAI AOLAN MARINE ORGANISM TECHNOLOGY CO., LTD. Applicant after: Lvye Investment Group Co., Ltd. Address before: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant before: Shandong International Biotechnology Park Development Co., Ltd. Applicant before: YANTAI AOLAN MARINE ORGANISM TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yipeng Inventor after: Zhang Jianbai Inventor after: Zhang Shumin Inventor after: Xie Zeping Inventor before: Wang Yipeng Inventor before: Zhang Shumin Inventor before: Xie Zeping |
|
CB03 | Change of inventor or designer information |